ESTRO 2025 - Abstract Book

S2131

Clinical - Urology

ESTRO 2025

Conclusion: The HypoFocal phase II trial is the first trial do demonstrate safety and feasibility of focal dose escalation based on mpMRI and PSMA-PET in MHRT and HDR-BT+EBRT in intermediate and high risk PCa patients. Particularly, HDR-BT offers good toxicity and QoL profiles. Current BRFS rates suggest high effectiveness of focal ablative microboosting. The HypoFocal-SBRT phase III trial will investigate the oncological benefit of this approach.